Search

Your search keyword '"Karam, J.A."' showing total 14 results
Start Over Author "Karam, J.A."
14 results on '"Karam, J.A."'

1. LBA66 IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection

Author

Bex, A., primary, Uzzo, R., additional, Karam, J.A., additional, Master, V.A., additional, Donskov, F., additional, Suárez, C., additional, Albiges, L., additional, Rini, B.I., additional, Tomita, Y., additional, Kann, A., additional, Procopio, G., additional, Massari, F., additional, Zibelman, M., additional, Antonyan, I., additional, Huseni, M., additional, Basu, D., additional, Ci, B., additional, Leung, W., additional, Khan, O., additional, and Pal, S.K., additional

Published
2022
Full Text
View/download PDF

2. 678P Cytoreductive nephrectomy (CN) for patients with metastatic sarcomatoid and/or rhabdoid (S/R) renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (ICI)

Author

Hahn, A.W., primary, Viscuse, P.V., additional, Pieretti, A., additional, Wiele, A.J., additional, Jonasch, E., additional, Gao, J., additional, Zurita, A.J., additional, Shah, A.Y., additional, Campbell, M.T., additional, Sharma, P., additional, Wood, C.G., additional, Tannir, N.M., additional, Karam, J.A., additional, and Msaouel, P., additional

Published
2021
Full Text
View/download PDF

4. Glycosaminoglycan (GAG) scores for surveillance of recurrence in Leibovich Points ≥5 non-metastatic clear cell renal cell carcinoma: AURORAX-0087A trial in progress report

Author

Dabestani, S., primary, Azawi, N.H., additional, Barber, N., additional, Bex, A., additional, Campi, R., additional, Capitanio, U., additional, Gatto, F., additional, Giles, R., additional, Hakimi, A.A., additional, Järvinen, P., additional, Karam, J.A., additional, Ljungberg, B., additional, Lund, L., additional, Maddineni, S.B., additional, Marconi, L., additional, Master, V., additional, Minervini, A., additional, Nielsen, T.K., additional, Nisen, H., additional, Rochester, M., additional, Stewart, G.D., additional, and Nair, R., additional

Published
2020
Full Text
View/download PDF

5. Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma

Author

Wallen, E.M., Parker, J.S., Moore, D.T., Kim, W.Y., Kimryn Rathmell, W., Powles, T., Royal Free Hospital, London, United Kingdom, Beckermann, K.E., Maygarden, S.J., Vincent, B.G., Bortone, D.S., Wood, C.G., Milowsky, M.I., Whisenant, J.G., Ferguson, J.E., Davis, N.B., Karam, J.A., and Haake, S.M.

Abstract

BACKGROUND. Surgery remains the frontline therapy for patients with localized clear cell renal cell carcinoma (ccRCC); however, 20%–40% recur. Angiogenesis inhibitors have improved survival in metastatic patients and may result in responses in the neoadjuvant setting. The impact of these agents on the tumor genetic heterogeneity or the immune milieu is largely unknown. This phase II study was designed to evaluate safety, response, and effect on tumor tissue of neoadjuvant pazopanib. METHODS. ccRCC patients with localized disease received pazopanib (800 mg daily; median 8 weeks), followed by nephrectomy. Five tumors were examined for mutations by whole exome sequencing from samples collected before therapy and at nephrectomy. These samples underwent RNA sequencing; 17 samples were available for posttreatment assessment. RESULTS. Twenty-one patients were enrolled. The overall response rate was 8 of 21 (38%). No patients with progressive disease. At 1-year, response-free survival and overall survival was 83% and 89%, respectively. The most frequent grade 3 toxicity was hypertension (33%, 7 of 21). Sequencing revealed strong concordance between pre- and posttreatment samples within individual tumors, suggesting tumors harbor stable core profiles. However, a reduction in private mutations followed treatment, suggesting a selective process favoring enrichment of driver mutations. CONCLUSION. Neoadjuvant pazopanib is safe and active in ccRCC. Future genomic analyses may enable the segregation of driver and passenger mutations. Furthermore, tumor infiltrating immune cells persist during therapy, suggesting that pazopanib can be combined with immune checkpoint inhibitors without dampening the immune response. FUNDING. Support was provided by Novartis and GlaxoSmithKline as part of an investigator-initiated study.

Published
2020
Full Text
View/download PDF

6. A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC)

Author

Campbell, M.T., primary, Martin, S., additional, Tam, A.L., additional, Sheth, R.A., additional, Singh, S., additional, Ahrar, K., additional, Slack Tidwell, B., additional, Rao, P., additional, Karam, J.A., additional, Wood, C.G., additional, Tannir, N.M., additional, Jonasch, E., additional, Gao, J., additional, Shah, A.Y., additional, Blando, J.M., additional, Duan, F., additional, Basu, S., additional, Allison, J., additional, and Sharma, P., additional

Published
2019
Full Text
View/download PDF

7. Prognostic value of the systemic inflammation modified Glasgow Prognostic Score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration

Author

Soria, F., primary, D’Andrea, D., additional, Karam, J.A., additional, Wood, C.G., additional, Rouprêt, M., additional, Margulis, V., additional, Karakiewicz, P.I., additional, Briganti, A., additional, Raman, J.D., additional, Bensalah, K., additional, Lotan, Y., additional, Gontero, P., additional, Remzi, M., additional, Gust, K., additional, and Shariat, S.F., additional

Published
2019
Full Text
View/download PDF

8. P081 - Glycosaminoglycan (GAG) scores for surveillance of recurrence in Leibovich Points ≥5 non-metastatic clear cell renal cell carcinoma: AURORAX-0087A trial in progress report

Author

Dabestani, S., Azawi, N.H., Barber, N., Bex, A., Campi, R., Capitanio, U., Gatto, F., Giles, R., Hakimi, A.A., Järvinen, P., Karam, J.A., Ljungberg, B., Lund, L., Maddineni, S.B., Marconi, L., Master, V., Minervini, A., Nielsen, T.K., Nisen, H., Rochester, M., Stewart, G.D., and Nair, R.

Published
2020
Full Text
View/download PDF

13. Converting gallbladder absorption to secretion: The role of intracellular calcium

Author

Moser, A.J., Abedin, M.Z., Cates, J.A., Giurgiu, D.I.N., Karam, J.A., and Roslyn, J.J.

Abstract

Background. Experimental cholelithiasis is associated with elevated biliary calcium concentration and altered gallbladder absorption. Recent studies showed that extracellular calcium ([Ca^2^+]"e"c) plays a role in regulating gallbladder ion transport. The extent to which intracellular calcium ([Ca^2^+]"i"c) mediates the changes in gallbladder ion transport is not clear. We hypothesize that [Ca^2^+]"i"c is an important regulator of gallbladder ion transport. Methods. Prairie dog gallbladders were mounted in Ussing chambers, standard electrophysiologic parameters were recorded, and unidirectional Na^+, Cl^-, and H"2O fluxes were measured before and after mucosal exposure of 10^-^5 mol/L calcium ionophore A23187 was performed. Results. A23187 caused an increase in transepithelial short-circuit current and potential difference and a decrease in transepithelial resistance. A23187 inhibited mucosa to serosa Cl^- flux and stimulated serosa to mucosa Na^+ flux, resulting in increased net Cl^- secretion and a decreased net Na^+ absorption. A23187 converted H"2O from absorption to secretion. Transepithelial short-circuit current effect of A23187 was delayed by indomethacin pretreatment and was completely blunted by low bathing Ca^2^+. Conclusions. This is the first demonstration that increased [Ca^2^+]"i"c converts the gallbladder from its normal absorptive state to a secretory one. Furthermore [Ca^2^+]"i"c appears to regulate ion transport through mechanisms that are partially prostaglandin-dependent. Studies are necessitated to define possible links between gallbladder secretion of Cl^- and H"2O and mucus hypersecretion, a well-described phenomenon associated with cholesterol gallstone formation.

Published
1996
Full Text
View/download PDF

14. 735 - Prognostic value of the systemic inflammation modified Glasgow Prognostic Score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration.

Author

Soria, F., D'Andrea, D., Karam, J.A., Wood, C.G., Rouprêt, M., Margulis, V., Karakiewicz, P.I., Briganti, A., Raman, J.D., Bensalah, K., Lotan, Y., Gontero, P., Remzi, M., Gust, K., and Shariat, S.F.

Subjects
*CARCINOMA, *LOGISTIC regression analysis, *INFLAMMATION, *RENAL cancer
Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results